Clinical Trials List
2019-09-01 - 2026-12-31
Phase II
Recruiting5
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
Merck Sharp & Dohme (I.A.) LLC
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Yao-Lung Kuo Division of Plastic Surgery
- Shang-Hung Chen Division of Hematology & Oncology
- Chun-Hui Lee Division of Hematology & Oncology
- 黃建璋 Division of General Surgery
- Ya-Ting Hsu Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
- 楊舜如 Division of Hematology & Oncology
- Zhu-Jun Loh Division of General Surgery
- Wei-Pang Chung Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chih-Jung Chen Division of General Surgery
- Chen-Teng Wu Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- Yao-Chung Wu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳彥仰 Division of Hematology & Oncology
- 陳彥豪 Division of Hematology & Oncology
- Shau-Hsuan Li Division of Hematology & Oncology
- 賴香蘭 Division of Hematology & Oncology
- Tai-Jan Chiu Division of Hematology & Oncology
- Yu-Li Su Division of Hematology & Oncology
- 吳佳哲 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 褚乃銘 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
11 participants
-
Global
260 participants
